tradingkey.logo

Neuronetics rises on upbeat 2025 revenue forecast

ReutersMar 4, 2025 3:38 PM

Shares of Pennsylvania-based medtech firm Neuronetics STIM.O rise 8.2% to $4.61

Company forecasts 2025 revenue between $145 million and $155 million, above analysts' estimate of $93.55 million, according to data compiled by LSEG

Company, which offers its NeuroStar device to treat major depressive disorder (MDD), posts Q4 revenue of $22.49 million, beating analysts' estimates of $19.63 million

In the last 12 months, STIM has fallen 41.5%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI